Compounds > cgc 11047
Page last updated: 2024-11-11

cgc 11047

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CGC 11047: may prove useful in promoting regression of choroidal neovascularization [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9822383
CHEMBL ID4296681
MeSH IDM0504975

Synonyms (17)

Synonym
206991-64-2
cgc-11047
sl 47
sl 11047
hu43305r7o ,
cdc 11047
cgc 11047
unii-hu43305r7o
2-butene-1,4-diamine, n,n'-bis(3-(ethylamino)propyl)-, tetrahydrochloride, (z)-
CHEMBL4296681
cgc-11047 hcl
206991-64-2 (hcl)
(z)-n1,n1'-(but-2-ene-1,4-diyl)bis(n3-ethylpropane-1,3-diamine) tetrahydrochloride
(z)-n,n'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine;tetrahydrochloride
CS-0006318
pg-11047 (tetrahydrochloride)
HY-16394
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID58070The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID285446Prevention of Cryptosporidium parvum infection in TCR alpha deficient-mouse pretreated with 50 mg/kg/day, po for 2 days prior to oocyst infection and continued for 5 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model.
AID103583Growth inhibitory activity was measured for human MCF-7 tumor cell line.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58218The concentration levels of spermine (SP) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID421197Antitumor activity against human MCF7 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID58079The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID214255Growth inhibitory activity was measured for human U251MG NCI tumor cell line.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58080The concentration levels of spermidine (SD) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58071The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58064The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58069The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID8694Growth inhibitory activity was measured for human A549 tumor cell line.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID421191Antitumor activity against human DU145 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID58089The concentration levels of spermidine (SD), evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58084The concentration levels of spermidine (SD) evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58073The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID421194Antitumor activity against human A549 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID421193Antitumor activity against human PC3 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID58222The concentration levels of spermine (SP) evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID55811Growth inhibitory activity was measured for human DU145 tumor cell line.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID285449Anticryptosporidial activity against Cryptosporidium parvum infected TCR alpha deficient-mouse assessed as prevention of oocyst shedding at 134 mg/kg/day after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model.
AID58224The concentration levels of spermine (SP), evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58062The concentration levels of analogue evaluated in DU145 cells treated with the compound concentration of 0.02 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID83766Growth inhibitory activity was measured for human HT-29 tumor cell line.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58086The concentration levels of spermidine (SD), evaluated in DU145 cells treated with the compound concentration of 0.02 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID421196Antitumor activity against human U251MG cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID58078The concentration levels of putrescine (PU) evaluated in DU145 cells treated with the compound concentration of 5 uM on fifth day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID58227The concentration levels of spermine (SP), evaluated in DU145 cells treated with the compound concentration of 5 uM on third day of treatment.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
AID421195Antitumor activity against human HT-29 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID156179Growth inhibitory activity was measured for human PC-3 tumor cell line.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's6 (85.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.15 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
spermine
[no description available]		2.0310polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.0310alpha-amino acid;
fluoroamino acid		trypanocidal drug
entinostat
[no description available]		3.1410benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
n(1),n(11)-diethylnorspermine
N(1),N(11)-diethylnorspermine: structure given in first source		3.1410
n(1), n(12)-diethylspermine
N(1), N(12)-diethylspermine: structure in first source. N(1),N(12)-diethylspermine : A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group.		3.5220polyazaalkane;
secondary amino compound;
substituted spermine;
tetramine		antineoplastic agent
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		3.1410dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
n(1),n(14)-bis(ethyl)homospermine
N(1),N(14)-bis(ethyl)homospermine: structure given in first source; depletes polyamines and inhibits the growth of tumor cells in tissue culture		3.1410
mdl 27695
MDL 27695: structure given in first source		3.1410
be 4-4-4-4
BE 4-4-4-4: structure given in first source		3.1410
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		3.1410antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
cgc 11093
CGC 11093: may prove useful in promoting regression of choroidal neovascularization		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
Cryptosporidium Infection
[description not available]		02.0310
Cryptosporidiosis
Intestinal infection with organisms of the genus CRYPTOSPORIDIUM. It occurs in both animals and humans. Symptoms include severe DIARRHEA.		02.0310
Breast Cancer
[description not available]		02.9610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9610
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0510
Cancer of Lung
[description not available]		02.4520
Cancer of Prostate
[description not available]		02.0510
Lung Neoplasms
Tumors or cancer of the LUNG.		02.4520
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0510
Choroid Neovascularization
[description not available]		02.0310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Rupture
Forcible or traumatic tear or break of an organ or other soft part of the body.		02.0310
Neovascularization, Optic Disc
[description not available]		02.0310
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		02.0310
Retinal Neovascularization
Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.		02.0310
Experimental Hepatoma
[description not available]		02.0310
Carcinoma, Oat Cell
[description not available]		02.0410
Carcinoma, Non-Small Cell Lung
[description not available]		02.0410
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.0410
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		02.0410